|
U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH NIH News National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) <http://www.niddk.nih.gov/>
For Immediate Release: Wednesday, March 15, 2023 CONTACT: Alyssa Voss, 301-496-3583, <e-mail:niddkmedia@xxxxxxxxxxxx> MEDIA AVAILABILITY NIH-SUPPORTED TRIAL SHOWS ARTIFICIAL PANCREAS IMPROVES BLOOD GLUCOSE CONTROL IN YOUNG CHILDREN WHAT Artificial pancreas technology improved blood glucose control in young children between ages 2 and 5 with type 1 diabetes, according to the results of the Pediatric Artificial Pancreas (PEDAP) Trial, a 13-week randomized controlled trial
conducted at three pediatric diabetes centers across the United States. The study was funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health, and results were published in the New England
Journal of Medicine < http://www.nejm.org/doi/full/10.1056/NEJMoa2210834>. The artificial pancreas, also known as closed-loop control, is an “all-in-one” diabetes management system that tracks blood glucose levels using a continuous glucose monitor (CGM) and automatically delivers the insulin when needed using
an insulin pump. The system replaces reliance on testing by fingerstick or CGM with delivery of insulin by multiple daily injections or a pump controlled by the patient or caregiver. The trial enrolled 102 participants between ages 2 and 5, a particularly challenging population when it comes to glycemic control, and randomly assigned them to either the artificial pancreas group or the standard care comparison group.
The artificial pancreas group received training on how to use the study device — an insulin pump programmed with Control-IQ insulin dosing technology — and a CGM. The standard care group continued to use their pre-study method of blood glucose management and
were trained to use the study CGM. During the 13 weeks, participants in the artificial pancreas group spent 12% more time — approximately three hours per day — within their target blood glucose range compared to the standard care group. The greatest difference in blood glucose
control was seen at nighttime, between 10 p.m. and 6 a.m., with artificial pancreas participants spending 18% more time in range than the standard care group. Nighttime control is especially challenging to maintain in children with type 1 diabetes.
Additional measurements of blood glucose control also improved, similar to findings seen in previous artificial pancreas trials in older children and adults. The trial was conducted at the Center for Diabetes Technology at the University of Virginia, Charlottesville; the Barbara Davis Center for Diabetes at the University of Colorado, Aurora; and Stanford University, Palo Alto, California. Due
to emergency pandemic restrictions at the time of the study, more than 80% of the device trainings, and 90% of the study visits overall occurred virtually, suggesting the suitability of the technology for use in remote and underserved areas.
The study also assessed safety of using the artificial pancreas device in young children. Similar numbers of severe hypoglycemia occurred among both study groups. One instance of diabetic ketoacidosis occurred in the artificial pancreas
group due to a problem with the insulin pump tubing called infusion set failure.
Study funding was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (grant # U01DK127551). Tandem Diabetes Care provided the investigational closed-loop insulin pumps and infusion supplies and Dexcom Inc.
provided the CGM supplies used in the trial. WHO Guillermo Arreaza-Rubin, M.D., program director in NIH’s National Institute of Diabetes and Digestive and Kidney Diseases, the study’s lead funder, is available to comment on this study. REFERENCE Wadwa, R.P., et al. Randomized, controlled trial of automated insulin delivery with virtual visits in young children with type 1 diabetes. New England Journal of Medicine. March 16, 2023. DOI: 10.1056/NEJMoa2210834
The NIDDK, a component of the National Institutes of Health (NIH), conducts and supports research on diabetes and other endocrine and metabolic diseases; digestive diseases, nutrition and obesity; and kidney, urologic and hematologic diseases.
Spanning the full spectrum of medicine and afflicting people of all ages and ethnic groups, these diseases encompass some of the most common, severe, and disabling conditions affecting Americans. For more information about the NIDDK and its programs, see http://www.niddk.nih.gov. About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting
and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit <https://www.nih.gov>. NIH...Turning Discovery into Health -- Registered, U.S. Patent and Trademark Office ### This NIH News Release is available online at: <https://www.nih.gov/news-events/news-releases/nih-supported-trial-shows-artificial-pancreas-improves-blood-glucose-control-young-children> <http://service.govdelivery.com/service/subscribe.html?code=USNIH_1>. If you subscribed via the NIH LISTSERV, go to <https://list.nih.gov/cgi-bin/wa.exe?A0=nihpress>. |
